摘要
目的 分析芪龙胶囊联合依达拉奉右莰醇、丁苯酞对急性脑梗死患者血清淀粉样蛋白(serum amyloid protein, SAA)、胶质纤维酸性蛋白(glial fibrillary acidic protein, GFAP)、泛素羧基末端水解酶-1(ubiquitin-carboxy-terminal hydrolase 1,UCH-L1)及神经功能的影响。方法 2022年1月-2024年1月医院收治的急性脑梗死患者90例,通过随机数字表法分为对照组(45例)与联合组(45例)。对照组予以依达拉奉右莰醇、丁苯酞治疗,联合组采用芪龙胶囊联合依达拉奉右莰醇、丁苯酞治疗,均治疗2周。比较两组治疗前、治疗2周后中医证候积分、血清SAA、GFAP、UCH-L1、脑部血流灌注情况,治疗前、治疗1周、治疗2周后神经功能,治疗期间安全性。结果 干预期间,联合组脱落2例,对照组脱落1例。与治疗前比较,治疗2周后,两组面色[白光]白、言语謇涩、半身不遂、气短乏力评分,血清SAA、GFAP、UCH-L1水平降低,且组间比较联合组更低(P<0.05)。治疗前、治疗1周、治疗2周后两组美国国立卫生研究院卒中量表(National Institutes of Health Stroke Scale, NIHSS)评分均呈降低趋势,且治疗1周、治疗2周后组间比较联合组更低(P<0.05)。与治疗前比较,治疗2周后,两组大脑中动脉舒张压末期血流速度(end diastolic blood flow velocity, EDV)、收缩期峰值流速(peak systolic flow velocity, PSV)、平均血流速度(mean velocity, Vm)水平升高,且组间比较联合组更高(P<0.05)。治疗期间,研究对象均未因不良反应中断治疗的进行,两组不良反应发生率类似(P>0.05)。结论 芪龙胶囊联合依达拉奉右莰醇、丁苯酞可改善急性脑梗死患者中医证候积分,改善神经功能,可能机制为调节SAA、GFAP、UCH-L1表达,控制神经细胞损伤,改善脑部血流灌注情况,安全性良好。
Objective To analyze the effects of Qilong Capsule(芪龙胶囊)combined with edaravone dextrocamphorol and butylphthalein on serum amyloid protein(SAA),glial fibrllary acidic protein(GFAP),ubiquitin-carboxy-terminal hydrolase 1(UCH-L1)and nerve function in patients with acute cerebral infarction.Methods Ninety patients with acute cerebral infarction admitted to the hospital from 202201 to 202401 were divided into the control group(45 cases)and the combination group(45 cases)by random number table method.The control group was treated with edaravone dextrocamphorol and butylphthalein,and the combined group was treated with Qilong Capsule combined with edaravone dextrocamphorol and butylphthalein for 2 weeks.Traditional Chinese medicine syndrome scores,serum levels of SAA,GFAP and UCH-LI,cerebral blood perfusion,neurological function before treatment,1 and 2 weeks after treatment,and the safety during treatment were compared between the two groups.Results During the intervention period,2 cases fell off in the combined group and 1 case fell off in the control group.Compared with those before treatment,afer 2 weeks of treatment,the scores of pale complexion,awkward speech,hemiplegia,shortness of breath and fatigue and the serum levels of SAA,GFAP and UCH-LI in the two groups were lower and those in the combined group were significantly lower than those of the control group(P<0.05).The National Institutes of Health Stroke Scale(NIHSS)score of the two groups showed a decreasing trend before treatment,1 and 2 weeks after treatment,and the score of the two groups was significantly lower in the combination group(P<0.05).Compared with those before treatment,after 2 weeks of treatment,the end diastolic blood flow velocity(EDV),peak systolic flow velocity(PSV)and mean velocity(Vm)of middle cerebral artery in the two groups increased,and the levels were significantly higher in the combined group(P<0.05).During treatment,none of the subjects stopped treatment due to adverse reactions,and the incidence of adverse reactions was similar between the two groups(P>0.05).Conclusion Qilong Capsule combined with edaravone dextrocamphorol and butaphthalein can improve traditional Chinese medicine syndrome scores and nerve function in patients with acute cerebral infarction.The possible mechanism is to regulate the expressions of SAA,GFAP and UCH-L1,control the nerve cell injury and improve the cerebral blood perfusion,with good safety.
作者
张倩
王淼
吕月
卢雅丹
高颖
李健
ZHANG Qian;WANG Miao;LYU Yue;LU Yadan;GAO Ying;LI Jian(Tangshan Workers Hospital,Tangshan 063000,Hebei,China)
出处
《中华中医药学刊》
2025年第10期247-250,共4页
Chinese Archives of Traditional Chinese Medicine
基金
河北省医学科学研究课题计划项目(20240967)。
关键词
芪龙胶囊
依达拉奉右莰醇
丁苯酞
急性脑梗死
淀粉样蛋白
胶质纤维酸性蛋白
泛素羧基末端水解酶-1
神经功能
Qilong Capsule(芪龙胶囊)
edaravone dextrocamphenol
butylphthalein
acute cerebral infarction
amyloid protein
glial fibrillary acidic protein
ubiquitin carboxy-terminal hydrolase 1
neural function
作者简介
张倩(1989-),女,河北唐山人,主管中药师,学士,研究方向:药物的临床应用;通讯作者:吕月(1984-),女,河北唐山人,副主任医师,学士,研究方向:脑血管病。E-mail:lvyue202424@163.com。
